2028TiP Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
| Autor: | Mazieres, J., Duruisseaux, M., Curcio, H., Morizane, C., Galot, R., Rottey, S., Stratmann, J.A., Ma, Y., Bouzaggou, M., Geng, L., Wermke, M. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S1076-S1077 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|